Brind.
From Aspirin Use in Chronic Kidney Disease Not Linked to Major CV Event Reduction

How could the ATTACK trial findings affect England's clinical guidelines for CKD?

Possible What happens if… A possibility worth considering, not a forecast.

Aspirin trial results may prompt changes to CKD treatment protocols in England. The ATTACK trial, which examined the use of low-dose aspirin in patients with chronic kidney disease (CKD) across primary care practices in the U.K., found no statistically significant difference between aspirin 75 mg and usual care regarding major cardiovascular events or all-cause mortality. This finding suggests that aspirin may not be a primary preventive measure for this population. As England is the primary jurisdiction for the National Health Service (NHS), these results could influence the review and potential revision of national clinical guidelines and operational protocols for CKD management.

Reported by 1 independent outlet Written Tuesday
Effect
Mild negative
How direct
Brind's reasoning
When
Within months
The story
No new developments lately

How it reaches England

Reported by news outletsBrind's reasoning

Tap any step to see the evidence behind it.

The facts so far

As reported. Each one links to where it comes from.

  • The ATTACK trial involved 4,633 patients with CKD.healio.com
  • Patients were randomly assigned to aspirin 75 mg vs. usual care.healio.com
  • Results showed no significant differences regarding major CV events or all-cause mortality.healio.com
  • The trial was underpowered, and further research is required.healio.com

Why it matters

The management of chronic kidney disease is a major public health concern, and national guidelines dictate how millions of patients are treated. If the current standard of care for CKD patients includes aspirin for primary prevention, these trial results could prompt a review of that practice, potentially leading to changes in prescribing habits across the NHS.

This trial was one of the first significantly sized studies to examine this question in CKD. While the results were not statistically significant, the findings reinforce the need for further research, such as meta-analyses, to confirm or refute the balance between the benefits and harms of aspirin in this high-risk population.

What we don't know yet

  • Will the ongoing meta-analysis pool of data confirm or refute the ATTACK trial's findings?
  • What specific changes, if any, would be made to NHS operational protocols based on these results?

What would change this answer

The meta-analysis confirms the lack of benefit of aspirin in CKD.The effect on England would become stronger and more certain, potentially leading to immediate guideline revisions.
New, larger trials show a significant benefit of aspirin in CKD.The effect would fade, as the current clinical guidelines would likely be maintained or adjusted in the opposite direction.

Who else could feel it

Other possible ripples from the same event.

Reporting

Keep going

The full eventAspirin Use in Chronic Kidney Disease Not Linked to Major CV Event Reduction Everything aboutEngland

Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.